Our study demonstrated the efficacy of ERβ agonists in attenuating cell proliferation, cell migration, and colony formation as well as inducing cell-cycle arrest and apoptosis of ERα+ breast cancer cell lines. The gene discussed is ESR2; the disease is breast carcinoma.